Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.40 |
| ▸ | SRC | P12931 | 5/20 | 0.37 |
| ▸ | KLK7 | P49862 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18597764 | 1.00 | USP30 (0.40) | USP30SRCKLK7KDM4EPKM | |
| SCHEMBL18597763 | 1.00 | USP30 (0.40) | USP30SRCKLK7KDM4EPKM | |
| SCHEMBL18597856 | 0.83 | USP30 (0.40) | USP30KLK7KDM4EPKMRORC | |
| SCHEMBL14902387 | 0.83 | USP30 (0.40) | USP30KLK7KDM4EPKMRORC | |
| SCHEMBL11994280 | 0.81 | KLK7 (0.43) | USP30SRCKLK7NR1H2RXRA | |
| SCHEMBL29582579 | 0.77 | USP30 (0.43) | USP30KLK7KDM4EPKMRORC | |
| SCHEMBL9929891 | 0.77 | USP30 (0.43) | USP30KLK7KDM4EPKMRORC | |
| SCHEMBL9929890 | 0.77 | USP30 (0.43) | USP30KLK7KDM4EPKMRORC | |
| SCHEMBL11996750 | 0.75 | USP30 (0.41) | USP30KLK7KDM4EPKMRORC | |
| SCHEMBL14900484 | 0.75 | CHRNA7 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-9724359-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-9682052-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2773335-B1 | OXALIC ACID AMIDES AS NEPRILYSIN INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND PREPARATION THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170020904-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334245-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2675795-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160074352-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-17 | — | — | US | disclosed |
| US-9150500-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140364603-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-8853427-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| US-8481044-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013067163-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | USP30 3480/4885SRC 3689/4885KLK7 241/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | USP30 3480/4885SRC 3689/4885KLK7 241/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | USP30 3480/4885SRC 3689/4885KLK7 241/4885 |
| US-20170020904-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | USP30 3249/4885SRC 3208/4885KLK7 259/4885 |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | USP30 3249/4885SRC 3208/4885KLK7 259/4885 |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | USP30 3480/4885SRC 3689/4885KLK7 241/4885 |
| US-20160074352-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | USP30 3480/4885SRC 3689/4885KLK7 241/4885 |
| US-20140364603-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | USP30 3249/4885SRC 3208/4885KLK7 259/4885 |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | USP30 3480/4885SRC 3689/4885KLK7 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.